-
Mashup Score: 2
Getting maximum value from these resources does first require that the specimens submitted to the Bank be of consistently high quality – that they comply with all requirements for labeling, collection, processing, storage, documentation, and shipping.
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Targeting KRAS in cancer - 2 day(s) ago
Nature Medicine – Recent developments in bioengineering and organic chemistry have enabled targeting of the previously ‘undruggable’ KRAS; this review summarizes the successes,…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20More Results: SWOG Trials That Keep on Giving | SWOG - 9 day(s) ago
S1216
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our @SWOGChair blog: More Results: SWOG Trials That Keep on Giving To keep @SWOG members informed of our research results, I'm highlighting important findings presented at two recent meetings, in #prostate cancer and rare #sarcomatoid carcinoma lung tumors https://t.co/S7v1ayFEx8 https://t.co/KVYurNewIm
-
-
Mashup Score: 1Validate User - 16 day(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Trans Dudes with Lady Cancer - 22 day(s) ago
A documentary film where the title says it all, except… They are housemates and were diagnosed in the same month.
Source: www.transdudeswithladycancer.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9A Sneak Peek at Spring in Seattle | SWOG - 27 day(s) ago
As with last fall’s group meeting, you can install our meeting app on your smart phone (Android or Apple), or you can simply use the online version in a browser (no installation needed).
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Invasive cancers typically evade immune surveillance through profound local and systemic immunosuppression, preventing their elimination or control. Targeting immune interventions to prevent or intercept premalignant lesions, before significant immune dysregulation has occurred, may be a more successful strategy. The field of cancer immune interception and prevention is nascent, and the scientific community has been slow to embrace this potentially most rational approach to reducing the global burden of cancer. This may change due to recent promising advances in cancer immunoprevention including the use of vaccines for the prevention of viral cancers, the use of cancer-associated antigen vaccines in the setting of precancers, and the development of cancer-preventative vaccines for high-risk individuals who are healthy but carry cancer-associated heritable genetic mutations. Furthermore, there is increasing recognition of the importance of cancer prevention and interception by national
Source: jitc.bmj.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Pilot Studies: When Efficacy Is Not the Primary Question | SWOG - 1 month(s) ago
Pilot studies can answer questions about whether a given trial design is feasible within the bounds of the National Clinical Trials Network and/or the NCI Community Oncology Research Program. They can tell us whether patients find a given intervention or approach acceptable, or whether we can enroll the right patients at the right rate of accrual.
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our @SWOGChair blog: Pilot Studies: When Efficacy Is Not the Primary Question Some of our studies are small-scale tests of methods & tools to be used in a scaled-up, definitive trial. @SWOG S1820, just published in the journal Cancer, was one such pilot. https://t.co/3hAvVZFwdu https://t.co/XJIiY3WMCa
-
-
Mashup Score: 1Better Integration of Community Oncologists into All We Do | SWOG - 2 month(s) ago
In recent years, community sites – specifically within the NCI Community Oncology Research Program (NCORP) – have accounted for about one-half of all SWOG-credited trial accrual. In fact, in 2023 the contribution of NCORP institutions was well over one-half of all enrollments. The challenge we face is ensuring community oncologists based at those sites are consistently well represented at the table through all stages of trial development and execution.
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11S2210 | SWOG - 2 month(s) ago
1. Disease Related Criteria Participant must have histologic diagnosis of prostate adenocarcinoma.Participant must have high or very high-risk disease defined by at least one of the following:cT3a to cT4xGrade Group 4 or 5 (Gleason sum 8-10)PSA > 20 ng/mL prior to registration Participant must have documented evidence of germline mutation (pathogenic/likely pathogenic variant) in BRCA2 or BRCA1…
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet-
.@SWOG S2210 is now enrolling! Testing #neoadjuvant carboplatin in patients with high-risk localized #prostatecancer and a #BRCA1 or #BRCA2 germline mutation (per local lab). https://t.co/R38dZgdBuz #PCSM #urology PI: @heatherhcheng @FredHutch @UWMedicine @PCF_Science @PCaPROMISE https://t.co/pduAcXOxdX
-
Our @SWOGChair blog: Biospecimen Quality: Protecting the Value of Our Biobank Currency Getting full value from our biobank resources requires that submissions be of consistently high quality. We've posted new resources to help make that easier to achieve. https://t.co/pAwvSEMZqN https://t.co/KzJ5HipK4Y